Literature DB >> 19542215

Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis.

Christine A Davies1, Ariane L Herrick, Lis Cordingley, Anthony J Freemont, Maria Jeziorska.   

Abstract

OBJECTIVES: Our aim was to establish which tissue components express advanced glycation/lipoperoxidation end products (AGEs) and their receptor (RAGE) in skin from patients with SSc, and how their expression relates to the disease subtypes and various clinical parameters.
METHODS: Skin punch biopsies were taken from the forearms of 61 SSc patients with lcSSc; 32 with calcinosis (lcSScCal) and 29 without lcSSc, 36 with the dcSSc subtype and 22 healthy control subjects. Immunohistochemical localization of AGE-CML [N(epsilon)-(carboxymethyl) lysine] and RAGE was assessed semi-quantitatively on the microvascular endothelium, dermal fibroblasts and the cutaneous extracellular matrix (ECM). The Kruskal-Wallis one-way ANOVA was used to compare data between groups.
RESULTS: AGE-CML expression on the papillary dermis ECM of lcSScCal was greater than in the control group (P = 0.016). The reticular dermis of lcSScCal showed increased AGE-N(epsilon)-(carboxymethyl) lysine (CML) expression compared with controls (P = 0.002), dcSSc (P = 0.024) and lcSSc (P = 0.025). Increased immunostaining for RAGE was seen on the reticular dermis ECM of the lcSScCal group compared with controls (P = 0.007). The lcSScCal subgroup showed statistically significant correlations for AGE-CML, and to a lesser extent for RAGE, with increased RP duration. There was no consistent evidence that the expression of AGE-CML or RAGE related to autoantibody status, clinical or histological skin score or patient age.
CONCLUSIONS: Our results indicate the possible contribution of AGE-CML deposition on the ECM in the dermis of the lcSScCal subgroup to the pathogenesis of formation of calcinotic deposits.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542215     DOI: 10.1093/rheumatology/kep151

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

1.  Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis.

Authors:  María Pilar Cruz-Domínguez; Grettel García-Collinot; Miguel A Saavedra; Gabriela Medina; Rosa Angélica Carranza-Muleiro; Olga Lidia Vera-Lastra; Luis J Jara
Journal:  Clin Rheumatol       Date:  2016-10-07       Impact factor: 2.980

Review 2.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 3.  Calcinosis in systemic sclerosis.

Authors:  Srijana Davuluri; Christian Lood; Lorinda Chung
Journal:  Curr Opin Rheumatol       Date:  2022-08-19       Impact factor: 4.941

4.  State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders.

Authors:  Graham Dinsdale; Sarah Wilkinson; Jack Wilkinson; Tonia L Moore; Joanne B Manning; Michael Berks; Elizabeth Marjanovic; Mark Dickinson; Ariane L Herrick; Andrea K Murray
Journal:  Microvasc Res       Date:  2020-04-19       Impact factor: 3.514

Review 5.  Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases.

Authors:  Fabrizio Guarneri; Paolo Custurone; Valeria Papaianni; Sebastiano Gangemi
Journal:  Antioxidants (Basel)       Date:  2021-01-09

6.  Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9.

Authors:  Joanna Nikitorowicz-Buniak; Xu Shiwen; Christopher P Denton; David Abraham; Richard Stratton
Journal:  J Invest Dermatol       Date:  2014-06-16       Impact factor: 8.551

7.  Skin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative Groups.

Authors:  Jolanta Dadoniene; Alma Cypiene; Ligita Ryliskyte; Rita Rugiene; Kristina Ryliškiene; Aleksandras Laucevičius
Journal:  Dis Markers       Date:  2015-12-31       Impact factor: 3.434

Review 8.  α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Authors:  Yosuke Kanno; En Shu
Journal:  Life (Basel)       Date:  2022-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.